Status:
UNKNOWN
Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Lead Sponsor:
University Hospital, Lille
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
18+ years
Brief Summary
The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermat...
Eligibility Criteria
Inclusion
- Adults
- moderate to severe atopic dermatitis
- treated by JAK inhibitors between december 2020 and september 2021
- inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy
- ineligibility to French ongoing clinical trials
Exclusion
- Children
- mild atopic dermatitis
- eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy
- eligibility to French ongoing clinical trials
- patients' opposition for the use of their records
- follow up \<3 months
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04761978
Start Date
September 1 2021
End Date
September 1 2022
Last Update
May 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lisle-sur-Tarn, France, 59037